Curida raises 75 million NOK

Published: 22 Dec 2017

(Elverum, 22 December 2017) Curida, the pharmaceutical Contract Development and Manufacturing Organization in Elverum, Norway, raises 75 million NOK. Canica AS and Klaveness Marine Finance AS join the current owners.


An investment of 50 MNOK is shared equally between Canica AS and Klaveness Marine Finance AS, who signs the deal on Friday 22 December. Investinor, an investment company owned and funded by the Norwegian Government, is considering an investment of a further 25 MNOK in Curida. Investinor will reach their final decision in January 2018. The largest shareholder in Curida after the transactions, will still be the holding company owned by Curida employees and management.


Curida Chairman Per S. Thoresen and CEO Leif Rune Skymoen state that Curida has passed an important milestone.


  • The employees and shareholders have been ambitious and successful. We have now attracted a team of solid investors, who will also add new knowledge and experience to our organization, Skymoen says.


The investment will drive further development of Curida operations and strengthen international sales activities. In addition, an acquisiton of a manufacturing company is to be announced in January 2018. Curida is an integrated part of the Norwegian life science scene, and the vision is to build a center for industrialization of medical innovation.


Mayor Erik Hanstad says that this is a great day for Curida, as well as for the city of Elverum:

  • We are happy and proud that Curida has taken a vital step towards their goal. We thank and congratulate all shareholders and employees, and we are immensely grateful for everything they bring to our city, Mayor Hanstad says.


Attending the ceremony in Elverum this Friday will also be Christer Kjos, CEO of Canica Holding AS, and Jon Chr. Syversen, General Manager of Klaveness Marine. Curida will be represented by Chairman Per S. Thoresen and CEO Leif Rune Skymoen.


CEO Christer Kjos of Canica Holding  AS puts emphasis on strengthening Norwegian industry and creating jobs in Norway:

  • Canica wants to team up also with Governmental funds, as we do with investinor in this case, Kjos says.
  • It is important for Canica to be a solid partner in this project. To us, it is great that we can contribute to creating jobs in Elverum. We see a strong potential in the CDMO market, both nationally and internationally, Kjos adds.


Klaveness Marine General Manager Jon Chr. Syversen looks forward to contributing to the further development of Curida:

  • We are impressed by the staff and the capabilities in Elverum, Syversen says.


General Manager Haakon Jensen in Investinor has observed Curida at close range for some time and is impressed by the way the company has progressed:

  • Curida is an exciting company with a long history and a great potential. The new owners add capital and new capabilities that will help the company on their journey towards international growth, Jensen says.


Employee representative Tone Bergerengen Holm is also enthusiastic:

  • We have all known that at some point Curida will need more capital. We are glad to see that it comes from strong investors.

About Curida
Curida is a Contract Development and Manufacturing Organization (CDMO), based in Norway, and serving the international pharmaceutical market. Curida is specialized on liquid products, employing bottle, nasal spray and Blow-Fill-Seal (BFS) technologies. Experience on operational excellence is spanning more than 40 years.

Curida has about 60 employees. The company acquired the former Takeda Nycomed manufacturing site in Elverum, Norway, in 2015. The Curida site covers 11.000 square meters and purpose-built for pharmaceutical manufacturing. Curida is an active partner of Oslo Cancer Cluster.


Contact persons

Per S. Thoresen, Chairman of Curida: mob +47 906 14 620

Leif Rune Skymoen, CEO of Curida: mob +47 996 49 419